60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001946563/000121390026099702/ea0305442-8k_60degree.htm